Supernus Pharmaceuticals
SUPN
Market cap $1.77B

32.10 USD

-0.06

0.19%

At close Oct 3, 4:00 PM EDT

After hours

32.10

+0.00

0%

1 day

-0.19%

5 days

4.05%

1 month

-7.52%

3 months

23.41%

6 months

-5.17%

Year to date

15.76%

1 year

18.49%

5 years

18.1%

About: Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Employees: 652

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

267% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $352K

1.84% more ownership

Funds ownership: 104.32% [Q1] → 106.17% (+1.84%) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 79

3% less funds holding

Funds holding: 247 [Q1] → 240 (-7) [Q2]

19% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 37

20% less capital invested

Capital invested by funds: $1.94B [Q1] → $1.56B (-$385M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$36

12%

upside

Avg. target

$36

12%

upside

High target

$36

12%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Piper Sandler

David Amsellem

62% 1-year accuracy

16 / 26 met price target

12%upside

$36

Neutral

Downgraded

11 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about SUPN published over the past 30 days

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her.

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate virtually in a fireside chat at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit on Thursday, September 26, 2024, at 8:40 a.m. ET.

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson's, with Qelbree's revenues being potentially seasonally influenced. Despite falling sales of older drugs, Supernus' strong financial position and promising pipeline, including SPN-820 for depression, suggest significant future upside is achievable, but not inevitable.

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Piper Sandler downgraded Supernus Pharmaceuticals Inc SUPN, saying that the anticipated surge in Qelbree prescriptions during the back-to-school season has not materialized as expected.

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts.

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD).

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Zacks Investment Research

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

The consensus price target hints at a 28.7% upside potential for Supernus (SUPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Annabel Samimy - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago.

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

See News Rankings

Charts implemented using Lightweight Charts™